From Nicotine & Tobacco Research:
In August 2019, the Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration, state and local health departments, and other clinical and public health partners began investigating a multistate outbreak of severe lung injuries that were first identified in July 2019 in Wisconsin and Illinois among persons with a reported history of e-cigarette, or vaping, product use. An ensuing investigation focused on understanding the extent, characteristics, and causes of the novel clinical syndrome, which was subsequently termed e-cigarette, or vaping, product use-associated lung injury (EVALI). As of February 18, 2020, a total of 2,807 hospitalized EVALI cases were reported to CDC from all 50 states, D.C., and two U.S. territories; 68 deaths were confirmed in 29 states and D.C. National emergency department data and active case reporting from state health departments documented a sharp increase in EVALI cases in August 2019, with case counts peaking in September 2019 and then steadily declining through early 2020.
This commentary describes the evidence-based approach used to identify the primary cause of EVALI and to curb the 2019 outbreak. We also discuss future research opportunities and public health practice considerations to prevent a resurgence of EVALI.
The article is available online from the journal Nicotine & Tobacco Research: